P7. Maternal-child infections
Oral Abstract Submission
Sarah B. Mulkey, MD, PhD
Fetal-Neonatal Neurologist
Children's National Health System
Rockville, MD
Disclosure: Centers for Disease Control and Prevention: Consultant, Technical assistance
Thrasher Research Fund: Grant/Research Support
Margarita Arroyave-Wessel, MPH
Program Manager, Telehealth
Children's National Health System
Washington, DC
Disclosure: Nothing to disclose
Colleen Peyton, PT, DPT
Pediatric Physical Therapist
Northwestern University
Chicago, IL
Disclosure: Nothing to disclose
Dorothy Bulas, MD
Radiologist
Children's National Health System
Washington, DC
Disclosure: Nothing to disclose
Gilbert Vezina, MD
Neuroradiologist
Children's National Health System
Washington, DC
Disclosure: Nothing to disclose
Yamil Fourzali, MD
Radiologist
Sabbag Radiologos
Barranquilla, Atlantico, Colombia
Disclosure: Nothing to disclose
Armando Morales, MD
Radiologist
Sabbag Radiologos
Barranquilla, Atlantico, Colombia
Disclosure: Nothing to disclose
Christopher Swisher, BS
Research coordinator
Children's National Health System
Washington, DC
Disclosure: Nothing to disclose
Caitie Cristante, BS
Research Coordinator
Children's National Health System
Washington, DC
Disclosure: Nothing to disclose
Stephanie Russo, BS
Research Coordinator
Children's National Health System
Washington, DC
Disclosure: Nothing to disclose
Youssef Kousa, DO, PhD
Child neurologist
Children's National Health System
Washington, DC
Disclosure: Nothing to disclose
Jiji Jiang, MS
Biostatistician
Children's National Health System
Washington, DC
Disclosure: Nothing to disclose
Michael Msall, MD
Developmental Pediatrics
University of Chicago
Chicago, IL
Disclosure: Nothing to disclose
Robert McCarter, ScD
Biostatistician
Children's National Health System
Washington, DC
Disclosure: Nothing to disclose
Adre du Plessis, MBChB, MPH
Fetal Neonatal Neurologist
Children's National Health System
Washington, DC
Disclosure: Thrasher Research Fund: Grant/Research Support
Carlos Cure, MD
Physician investigator
BIOMELAB
Barranquilla, Atlantico, Colombia
Disclosure: Nothing to disclose
Roberta L. DeBiasi, MD, MS
Chief, Pediatric ID and Professor, Pediatrics & Microbiology, Immunology, Tropical Medicine
Children’s National Health System/ George Washington Univ School of Medicine
Washington, District of Columbia
Disclosure: Nothing to disclose
Background : Congenital Zika syndrome (CZS) is seen in 5-12% of newborns from Zika virus (ZIKV) infected pregnancies and includes severe neurologic abnormalities. However, the majority of ZIKV-exposed newborns do not have CZS. The risk for neurodevelopmental impairment for infants without CZS following in utero ZIKV is not well known. The objective was to determine if infants without CZS exposed to ZIKV in utero, have normal neurodevelopment.
Methods : We performed a longitudinal study of neurodevelopment in Colombia for infants exposed to ZIKV in utero who had normal fetal brain MRI (Mulkey et al, JAMA Peds 2019) and normal head circumference at birth. Infant development was assessed by the Warner Initial Developmental Evaluation of Adaptive and Functional Skills (WIDEA) and the Alberta Infant Motor Scale (AIMS) between 6 and 18 months of age. In-person training was done by a neurologist. The AIMS were video-recorded and scored centrally. Interrater reliability for the novel method of video-based AIMS was determined. WIDEA and AIMS scores were converted to Z-scores compared to normative samples. We also compared development between infants with normal and non-specific findings on cranial ultrasound (US).
Results : 72 non-CZS infants had neurodevelopmental tests; 40 were at a mean (SD) of 5.7 (0.9) months and 66 were at 13.5 (3.2) months of age. Thirty-four had two assessments. The total WIDEA, social cognition, and mobility domain scores became more abnormal with postnatal age (Figure). The AIMS scores were similar to the normative sample. Three infants had an AIMS score < 2 SD’s below the norm. On cranial US, 19 infants (26%) had a non-specific finding (lenticulostriate vasculopathy, choroid plexus cysts, subependymal cysts, and/or calcification). Infants with an US finding had a lower WIDEA mobility score than infants with normal US (P=.054). There was a trend towards lower AIMS scores in infants with US findings compared to infants with normal US (P=.26). AIMS Interrater agreement on video-based scoring was good (ICC = 0.73, 95% CI 0.42, 0.87).
Conclusion : ZIKV-exposed infants without CZS are at risk for neurodevelopmental delay. Non-specific cranial US findings may represent mild ZIKV-related injury. Long-term neurodevelopmental follow-up is important for all ZIKV-exposed infants.
